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Abstract Bortezomib-based regimens have significant ac-
tivities in multiple myeloma (MM). In this study, we tested
the efficacy of a total therapy with a staged approach where
newly diagnosed MM patients received vincristine/adria-
mycin/dexamethsone (VAD). VAD-sensitive patients
(≥75% paraprotein reduction) received autologous hemato-
poietic stem cell transplantation (auto-HSCT), whereas less
VAD-sensitive patients (<75% paraprotein reduction) re-
ceived bortezomib/thalidomide/dexamethasone (VTD) for
further cytoreduction prior to auto-HSCT. On an intention-
to-treat analysis, a progressive increase of complete
remission (CR) rates was observed, with cumulative CR
rates of 48% after HSCT. Seven patients progressed leading
to three fatalities, of which two had central nervous system
disease. The 3-year overall survival and event-free survival
were 75.1% and 48.3%, respectively. Six patients devel-
oped oligoclonal reconstitution with new paraproteins. In
the absence of anticoagulant prophylaxis, no patients
developed deep vein thrombosis. The staged application
of VAD+/–VTD/auto-HSCT resulted in an appreciable
response rate and promising survivals. Our approach
reduced the use of bortezomib without compromising the
ultimate CR rate and is of financial significance for less
affluent communities.
Keywords Staged approach . VAD .VTD . Survival .
Oligoclonal reconstitution . CNS disease
Introduction
Multiple myeloma (MM) has a low possibility of cure.
However, important therapeutic improvements have been
made. Scheduled autologous hematopoietic stem cell
transplantation (auto-HSCT) after initial cytoreduction
has resulted in a complete remission/near-complete
remission (CR/nCR) rate of about 20% [1], which
translates into a benefit in overall survival (OS). Recently,
the advent of targeted therapy such as bortezomib results
in important advances in the treatment of MM. Bortezo-
mib, a proteasome inhibitor that inhibits nuclear factor
kappa B [2], leads to a CR/nCR rate of 10% in heavily
treated, refractory, and relapsing patients with MM [3, 4].
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Moreover, upfront use of bortezomib in combination with
chemotherapy has resulted in a CR rate about of 20% (17–
43%) even in the absence of auto-HSCT [5, 6]. This is an
important aspect in the management of MM as MM is a
disease of the elderly, with the majority of the patients
ineligible for auto-HSCT that leads to a high CR rate [1].
Furthermore, bortezomib is non-myelotoxic and hence
may be used in combination with conventional chemo-
therapy. Indeed, synergism of tumor cytotoxicity has been
demonstrated when chemotherapy is combined with
bortezomib, thus restoring chemosensitivity to previously
chemoresistant tumor cells [7, 8]. Based on these encour-
aging data, the upfront use of bortezomib in combination
with conventional chemotherapy has been tested in
younger patients before HSCT and in elderly patients
who are not HSCT candidates. Expectedly, the upfront use
of combined bortezomib and chemotherapy has resulted in
a CR rate of about 20–30% in elderly patients [9] and a
more encouraging CR rate of about 50% in younger
patients when followed by auto-HSCT [10, 11]. The
improved CR rates have translated into superior
progression-free survival and OS [12].
Both bortezomib and HSCT have emerged as impor-
tant components in the management of MM, although
their roles and timing relative to each other have not
been determined. Bortezomib is an expensive medication
with significant side effects. To optimally position
bortezomib and HSCT, we reasoned that patients reach-
ing a satisfactory response with conventional treatment
might not need additional cytoreduction with bortezomib
pre-HSCT. However, for patients with suboptimal re-
sponse to conventional treatment, additional cytoreduc-
tion with bortezomib pre-HSCT might improve the
outcome. Therefore, a staged approach was adopted in
which newly diagnosed myeloma patients who achieved
a ≥75% reduction in paraprotein level after standard
vincristine, adriamycin, and dexamethasone (VAD)
would proceed to auto-HSCT, whereas those with a
<75% paraprotein reduction would receive bortezomib,
thalidomide, and dexamethasone (VTD) for additional
cytoreduction prior to auto-HSCT.
≥75% <75%
VTD
Salvage  
Autologous
HSCT
VAD
RESPONSE
Fig. 1 Algorithm of patient treatment
Median age (years, range) 54 years (33–65)
Male/female 17/8
Paraprotein
IgG 12 (48%)
IgA 4 (16%)
IgD 2 (8%)
Light chain 7 (28%)
Durie–Salmon stage
IA 2 (8%)
IIA 4 (16%)
IIIA 13 (52%)
IIIB 6 (24%)
International staging system
I 7 (28%)
II 7 (28%)
III 11 (44%)
DAPK methylation (N=21) 4 (19%)
Median β2M (μg/mL, range) 4.67 μg/mL (1.92–13.2 μg/mL)
Normal: <1.42 μg/mL
Median serum albumin (g/L, range) 30 g/L (17–49 g/L)
Normal: 42–54 g/L
Median CD34 positive cell dose/kg body weight 5.56×106 (range: 2.88–20.4×106)
Median days to neutrophil engraftment 18 (10–29)
Table 1 Patient demographics
(N=25)
Ig immunoglobulin
International staging system [13]
Durie-Salmon staging system
[14]
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Materials ad methods
Patients, treatment algorithm, and protocol The study
started in October 2005. The median follow-up time was
17 months (range, 7–39 months). Inclusion criteria were
newly diagnosed MM with symptoms, age <65 years,
measurable disease, serum creatinine <3 times the upper
reference value (normal, 82–126 μmol/L), and adequate
liver function [15]. All patients received initial cytoreduc-
tion with three cycles of VAD. Those achieving ≥75%
reduction in paraprotein proceeded to HSC mobilization
with cyclophosphamide (4 g/m2 intravenously) and granu-
locyte colony stimulating factor (300 μg/day subcutane-
ously unit leukocyte recovery). Patients with <75%
reduction in paraprotein received VTD (bortezomib,
1.3 mg m−2day−1 intravenously on days 1, 4, 8, and 11;
thalidomide, 200 mg/day; and dexamethasone, 40 mg/d
orally from days 1–4 and days 8–11). Thalidomide and
bortezomib dosage was reduced to 75% for World Health
Organization grade III toxicity and omitted for grade IV
toxicity. Fourteen of the 25 patients proceeded to VTD
salvage therapy because of <75% reduction in paraprotein
level. Of these 14 patients, all received four cycles of VTD,
except one who had only three cycles of VTD due to grade
IV neurotoxicity. Auto-HSCT conditioning regimen com-
prised intravenous melphalan at 200 mg/m2. Four patients
did not receive auto-HSCT. Two patients opted for
allogeneic HSCT with HLA-identical siblings, and they
were censored after completion of VTD. The other two
patients had primary refractory disease or rapidly progres-
sive disease during VTD therapy. All patients received
thalidomide (100–200 mg/day) as maintenance therapy
regardless of whether VTD had been used. Prophylactic
cotrimoxazole for Pneumocystis jirovecii was routinely
prescribed. The protocol was approved by the institution
review board in accordance with the Declaration of
Helsinski, and informed consent was obtained from all
participating patients. The treatment algorithm was shown
in Fig. 1. Toxicity was reported after initial VAD and after
VTD according to the Common Terminology Criteria for
adverse events v3.0.
Staging and laboratory investigations MM workup includ-
ed bone marrow examination, skeletal survey, serum β2-
Table 2 Cumulative response after each stage of treatment
Post-VAD (N=25) Post-VTD (N=25) 3-month post-Auto-HSCTa (N=25) 3-month post-Auto-HSCT (N=21)
CR 1 (4%) 2 (8%) 12 (48%) 12 (57.1%)
nCR 3 (12%) 4 (16%) 1 (4%) 1 (4.8%)
VGPR 4 (16%) 8 (32%) 5 (20%) 3 (14.3%)
PR75 3 (12%) 9 (36%) 5 (20%) 5 (23.8%)
PR50 5 (20%) 0 0 0
MR 6 (24%) 0 0 0
NR 3 (12%) 2 (8%) 2 (8%) 0
VAD vincristine, adriamycin, dexamethsone, VTD velcade, thalidomide, dexamethasone, HSCT hematopoietic stem cell transplantation, CR
complete response, nCR near-complete response, VGPR very good partial response, PR75 partial response with 75–90% paraprotein reduction,
MR minor response, NR no response, PR50 partial response with 50–75% paraprotein reduction
a Intention-to-treat analysis
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Fig. 2 Overall survival and event-free survival of 25 patients
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microglobulin (β2M) level, serum protein electrophoresis
(SPE), urine protein electrophoresis, serum or urine
immunofixation, paraprotein level assay, and serum free
light chain (FLC) assay (Freelite, The Binding Site,
Birmingham, UK) [16]. All sera were assessed with SPE
and FLC immunoassays. Urine was assessed for monoclo-
nal FLC by immunofixation.
Response criteria All patients were analyzed on an
intention-to-treat basis. Bone marrow plasmacytosis and
paraprotein levels were assessed prior to treatment, after
VAD, after VTD, and 3 and 6 months after auto-HSCT.
Responses were defined according to standard criteria
[17]. CR was defined as complete resolution of disease
with absent paraprotein, as evidenced by a negative SPE
and immunofixation, and <5% plasma cells in the bone
marrow. nCR was defined as a negative SPE but positive
immunofixation. Partial response (PR) was sub-classified
into very good partial remission (VGPR, paraprotein
reduction ≥90%), PR75 (paraprotein ≥75% but <90%
reduction), and PR50 (paraprotein ≥50% but <75%
reduction). Minor response (MR) was defined as para-
protein reduction of ≥25% but <50%. No response (NR)
was defined as paraprotein reduction of <25%. Progres-
sion was defined as ≥25% paraprotein increase in two
consecutive tests 4 weeks apart. Relapse was defined as
reappearance of the paraprotein on immunofixation in CR
patients, positive SPE in the nCR patients, and/or
appearance of new bone lesions. For patients with light-
chain MM (LCMM), CR was defined as normalization of
the level and ratio of serum FLC and negative serum and
urine immunofixation. Oligoclonal reconstitution was
defined as the appearance of a new paraprotein not present
at diagnosis, which persisted for ≥4 weeks. Six of the
patients developed a paraprotein different from that at
diagnosis during CR or plateau phase and, hence, a “clonal
change”. However, the origin of the new clone was not
clear and might imply development of a second malig-
nancy entirely unrelated to the original disease. Therefore,
Table 3 Side effects after VAD and VTD
After VAD VAD (N=25) VTD (N=14)
Grade 3/4 myelotoxicity 10 (40%) 0
Sensory neuropathy (grade 2) 12 (48%) 12 (85.7%)
Tremor 2 (8%) 4 (28.6%)
Grade 1 2 3
Grade 3 0 1
Proximal muscle weakness 2 (8%) 4 (28.6%)
Grade 2 1 (4%) 2
Grade 3 1 (4%) 2
Mucositis (grade 2) 2 (8%) 0
Gastrointestinal 3 (12%) 7 (50%)
Constipation 2 (8%) 7
Grade 1 2 5
Grade 2 0 2
Epigastric pain 1 (4%) 0
Deep vein thrombosis 0 0
Infection/febrile episode 7 (28%) 4 (28.6%)
Fever 2 0
Hickman line infection 2 0
HSV sacral ulcer 1 0
Pneumonia/bronchitis 1 1
CMV hepatitis 1 0
Zoster 0 1
Folliculitis 0 1
Enterobactor 0 1
Steroid-induced diabetes mellitus 1 (4%) 1 (7%)
CMV cytomegalovirus, HSV herpes simplex virus
Table 4 Oligoclonal reconstitution in six myeloma patients
Case Original
paraprotein
New
paraprotein
Paraprotein
level
Time of onset of new
paraprotein
remark Outcome
C1 κ IgGκ WQ CR Same light chain Persisted for
11 months
C2 λ IgGλ WQ CR Same light chain Persisted ×
4 months
C3 IgAκ IgGκ CR Different heavy chain Persisted ×
13 months
C4 IgDλ IgGκ 8 g/L CR Different paraprotein Persisted ×
5 months
C5 IgGκ double
IgGκ
2.1 g/L PR75 Additional clone Persisted ×
5 months
C6 κ IgGκ 1.7 g/L CR A complete immunoglobulin with the
same light chain
Persisted ×
1 month
WQ too weak to quantitate, CR complete remission, PR75 partial response with 75% reduction in paraprotein
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Case 1: κ at diagnosis Case 1: Gκ during Complete Remission
SPE IgA IgM κ IgG λ SPE IgA IgM κ IgG  λ
SPE IgA IgM κ IgG λ SPE IgA IgM κ IgG  λ
SPE IgA IgM κ IgG λ SPE IgA IgM κ IgG  λ
SPE IgA IgM κ IgG λ SPE IgA IgM κ IgG  λ
Case 3: IgAκ at diagnosis Case 3: IgGκ after Complete Remission
Case 4: IgDλ at diagnosis Case 4: IgGκ during Complete Remission
IgD
Case 5: IgGK at Dxdiagnosis Case 5: double IgGK at diagnosis
Fig. 3 Oligoclonal reconstitution in MM patients. Upper left showed
clonal change of free kappa at diagnosis to IgGκ during complete
remission (CR). Upper right showed clonal change from IgAκ at
diagnosis to IgGκ during CR. Lower left showed clonal change from
IgDλ (arrows) plus free λ (arrowhead) at diagnosis to IgGκ during
CR. Lower right showed clonal change from single IgGκ at diagnosis
to double IgGκ during CR
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in the case of oligoclonal reconstitution, the absence of the
original paraprotein by serum/urine immunofixation still
qualified for CR.
Statistical analysis The primary endpoint was response
rate. Secondary endpoints were survivals. OS was defined
as time from commencement of induction therapy to death
or last follow-up. Event-free survival (EFS) was defined as
time from commencement of induction therapy to the date
of progression, relapse, or death. Survival curves were
plotted by Kaplan–Meier method.
Results
Patients The demographics of the patients were shown in
Table 1. There was an incremental upgrade of response
after each stage of treatment (Table 2). After VAD, 14
(56%) proceeded to receive VTD. The CR rate was 4%
after VAD, 8% after VTD, and 48% in an intention-to-
treat analysis after HSCT, or 57% for patients who
actually completed HSCT. All patients undergoing auto-
HSCT had at least PR75 pre-HSCT. The projected 3-year
OS was 75.1% (Fig. 2). Seven patients progressed, all
having DS stage III disease with ISS stage II in four and
stage III in three cases. The 3-year EFS was 48.3%
(median, 26 months; Fig. 2). Four patients died (all with
DS stage IIIA disease), one of primary refractory disease,
two of relapses after prior CR, and one of progression
from PR.
Side effects (Table 3)
After VAD, 12 (48%) patients developed grade 2 sensory
neurotoxicity, two (8%) tremor (one grade 1, one grade
2), three (12%) with GI side effects (two grade 1
constipation, one epigastric pain), and seven (28%)
infective/febrile episodes. After VTD, 11 (78.6%) had
sensory neuropathy (grade 3, N=4; grade 4, N=1). Of
these 11 VTD patients with sensory neuropathy, seven
already had grade 2 sensory neuropathy after VAD, of
which three had static grade 2 sensory neuropathy and
four had increased severity of neuropathy (neuropathy
increased from grade 2 to 3, N=3, and grade 2 to 4, N=1).
Another four patients with no neuropathy after VAD
developed neuropathy after VTD (grade 2, N=3; grade 3,
N=1).
Oligoclonal reconstitution Six patients developed oligo-
clonal reconstitution, five after CR (as defined by
disappearance of the initial paraprotein; Table 4). Three
patterns were observed. Cases 1, 2, and 6 with initially
LCMM developed a complete immunoglobulin parapro-
tein. Case 5 developed an additional paraprotein with the
same immunoglobulin subtype. Finally, cases 3 and 4
developed an entirely different paraprotein. For patients
with a measurable new paraprotein, the level appeared to
be stable over a period of 1–11 months (median, 5 months;
Fig. 3).
CNS relapse Patient P4 (Table 5) with stage IIIA IgA MM
achieved PR50 after VAD and CR with VTD. Acute spinal
Table 5 Characteristics and outcome of the seven patients with disease progression
Patient Paraprotein DS
stage
ISS stage
at
Diagnosis
Best
response
Time from treatment
to progression
(months)
Survival after
progression
(months)
Outcome Site of progression
P1 Light chain IIIA III CR 10 3 Death BM + skin
plasmacytoma +
circulating plasma cell
P2 IgG IIIA II CR 26 10+ Alive with
disease
BM
P3 IgG IIIA II PR75 13 4 death CNS + BM
P4 IgA IIIA III CR 18 5 death Extramedullary + BM
P5 IgG IIIB III Progressive
disease
5 8+ Alive with
disease
Pleural
P6 IgG IIIA II CR 21 14 Alive with
disease
BM
P7 IgG IIIA II VGPR 23 16 Alive with
disease
BM
Ig immunoglobulin, CR complete response, PR75 partial response with 75–90% paraprotein reduction, VGPR very good partial response, BM
bone marrow, CNS central nervous system
1024 Ann Hematol (2010) 89:1019–1027
cord compression developed a year after HSCT, with IgA
increasing to 2,020 mg/dL (normal <386 mg/dL). Mag-
netic resonance imaging showed an extensive thoracco-
lumbar extradural mass with cord compression (Fig. 4a).
He achieved a partial response after bortezomib-CMP
(cyclophosphamide, melphalan, and prednisolone) [8], but
died of disease progression 2 months afterwards. Patient 3
with DS IIIA MM achieved PR75 after VAD, which was
maintained with thalidomide after HSCT. Sudden diplopia
due to right abducens nerve palsy and skin nodules
developed 7 months after HSCT. Computerized axial
tomography did not reveal any abnormality. The cerebro-
spinal fluid showed elevated protein 1.36 g/L (normal <
0.6 g/L) and a cell count of 52 × 106/L with 96% plasma
cells (Fig. 4b). The serum paraprotein level resurged to
27 g/L. Bone marrow examination showed 28% pleomor-
phic plasma cells. He refused further treatment and died
4 weeks afterwards.
Discussion
In this study, the response to standard VAD was used to
dichotomized patients to a chemosensitive group (≥75%
paraprotein reduction after VAD) who proceeded directly to
auto-HSCT and a relative chemoresistant group (<75%
Fig. 4 a Sagittal fat-saturated SE T1W scan obtained after administration of intravenous gadolinium contrast agent showing an enhancing
epidural mass (arrows) in the posterior spinal canal compressing the thoracic cord. b Cerebrospinal fluid showed myeloma cells
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paraprotein reduction) who received additional cytoreduction
with VTD before auto-HSCT. We surmised that this staged
approach might maximize the reduction of neoplastic cells
prior to HSCmobilization and restrict the use of the expensive
bortezomib to chemoresistant patients.
There are several interesting observations. We achieved
a cumulative CR rate of >50% after auto-HSCT. Recent
studies showed that first-line use of bortezomib-based
regimens gave CR rate of up to 30% even without HSCT
[9]. Furthermore, total therapy using bortezomib-containing
regimens for initial cytoreduction prior to auto-HSCT
resulted in a CR rate of about 50% (43% to 56%) [10–
12]. Therefore, the results in this study provide an
alternative method of achieving an appreciable CR rate
with a reduced use of bortezomib. In less affluent countries
or health care systems, our approach offers a means of
alleviating the financial burden of bortezomib without
compromising the overall treatment results of patients with
MM.
Despite the relatively high CR rate after auto-HSCT in
our cohort, it is noteworthy that the CR rate only changed
from 4% to 8% when VTD was used in patients not
responding optimally to VAD. These results contrasted that
of the regimen (PAD, bortezomib, doxorubicin, dexameth-
asone) in untreated MM patients where the CR rate was
around 25% after PAD alone [10, 11]. While these results
could not be directly compared as different regimens were
used on dissimilar patient populations, this disparity might
be partially explained by the fact that only relatively
chemoresistant patients received VTD in our study.
On the other hand, using VAD upfront resulted in very
frequent (48%) sensory neuropathy prior to VTD. More-
over, eight had new onset or increased severity of
neuropathy after VTD. Therefore, it would have been more
preferable to use AD instead of VAD to avoid excessive
neuropathy without compromising the chemotherapy re-
sponse prior to VTD.
On follow-up, a significant number of patients devel-
oped a new paraprotein distinct from the one at diagnosis.
Indeed, development of isotypic change and oligoclonal
bands has been reported in about 10% of MM patients
undergoing HSCT [18]. The long-term outcome of these
new clones remains to be determined. If these new clones
represented expansion of minor subclones consequent to
effective elimination of major clones, this phenomenon of
oligoclonal reconstitution might become more common as
more effective treatment becomes available. Alternatively,
appearance of the new clone might represent clonal
evolution from the original clone. Case 5 who developed
two Gκ bands evolving from one Gκ at diagnosis might be
explained by this mechanism. Whatever the pathogenesis,
oligoclonal reconstitution affects the management of
patients. Firstly, the diagnosis of CR may be difficult. In
our case, we define CR as the absence of the original clone,
and hence, the emergence of another clone does not alter
the diagnosis of CR. Secondly, the long-term outcome of
these new clones in our patients is yet to be defined, which
might be transient [18].
Two of our patients developed central nervous system
(CNS) myeloma at progression in addition to cutaneous
deposition and plasma cell leukemia. This is a rare
complication [19, 20], and the factors predisposing to
CNS dissemination remain to be elucidated. However, it
would have been ideal if clonal analysis of the CSF plasma
cells had been performed.
Finally, deep vein thrombosis (DVT) did not occur in
any of our patients despite the omission of prophylaxis.
In Western patients, when thalidomide was combined
with dexamethasone or chemotherapy, the risk of DVT
might be increased to 10–27% [21]. Our observation
concurred with another study showing a low incidence of
DVT in a cohort of 85 Chinese MM patients receiving
thalidomide [22]. Moreover, the incidence of DVT in
Chinese has been shown to be much less frequent than
Caucasian patients to the extent that prophylaxis is not a
standard practice even in patients undergoing orthopedic
surgery [23, 24]. This disparity might at least be partially
explained by the absence of factor V Leiden and
prothrombin 20210 mutations, both hereditary thrombo-
philic tendencies prevalent in Caucasians, in the Chinese
population [25, 26]. Therefore, we believe that Chinese
patients do not require prophylactic aspirin while receiv-
ing thalidomide.
In conclusion, our VAD-VTD/auto-HSCT algorithm
resulted in a high response rate and promising survivals.
This staged approach has significant financial implications
in the treatment of MM.
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